Compounding evidence: management cites customer behavior, not just customer numbers, as proof the offering is winning
The model's full reasoning — Q1 2018 call → NOThe question asks whether management grounds its case for the business in observed customer or counterparty behavior from the recent period, rather than only in the company's own results, effort, or plans. Looking at the transcript, management discusses: - TransCon Growth Hormone Phase 3 trials (heiGHt, fliGHt, enliGHten) - TransCon PTH Phase 1 completed, Phase 3 planned - TransCon CNP Phase 1 dosing initiated The key evidence cited: - For fliGHt trial: "We are pleased with the response to fliGHt indicating interest on the part of patients and investigators to switch from daily to weekly growth hormone." This is somewhat behavioral - patients and investigators showing interest in switching. - For heiGHt trial: enrollment exceeded target with 161 subjects randomized - this is about trial enrollment, not customer behavior per se. - For TransCon PTH: advisory board of experts provided input - this is expert input, not customer behavior. The fliGHt trial response - "interest on the part of patients and investigators to switch from daily to weekly growth hormone" - is the closest to behavioral evidence. But is it described concretely? It says "we are pleased with the response" and "indicating interest" - this is somewhat generic. It doesn't describe specific patterns like patients enrolling faster than expected, or specific commitments. The heiGHt trial exceeded enrollment targets - but this is about clinical trial enrollment, which is a form of counterparty behavior (investigators and patients choosing to participate), but it's not really about customers buying or using the product. The question asks about "buyers, users, or partners" doing things that reveal genuine preference or commitment. Clinical trial enrollment could count, but the description is not very concrete - it just says enrollment exceeded target. For fliGHt, the description is "we are pleased with the response... indicating interest on the part of patients and investigators to switch" - this is somewhat generic. It doesn't describe specific behaviors like "patients are enrolling at X rate" or "investigators are requesting more sites." Management's case for the business rests mainly on: - Clinical trial progress and milestones - Pipeline advancement - Plans for Phase 3 programs - Financial position The behavioral evidence is thin. The fliGHt response is mentioned but not described concretely.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| LEGH | Legacy Housing Corporation | Q4 2023 | 2024-03-18 | C |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| AIRG | Airgain, Inc. | Q3 2023 | 2023-11-09 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| AEIS | Advanced Energy Industries, Inc. | Q2 2023 | 2023-08-03 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| M | Macy's, Inc. | Q4 2022 | 2023-03-02 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| AWRE | Aware, Inc. | Q3 2022 | 2022-10-30 | F |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| MOMO | Hello Group Inc. | Q3 2021 | 2021-11-30 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| AMGN | Amgen Inc. | Q3 2018 | 2018-10-30 | B+ |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
ULCC · Q1 2023 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management points to concrete recent-period behavior: over half of GoWild Pass sales so far are from customers with no prior travel history with Frontier, plus overwhelmingly positive feedback and customers taking the product to social media. They treat this observed adoption pattern as central proof that the offering is working and will keep growing, with the 90%+ repeat rate and $85–$100 per-passenger contribution goals still ahead of current results. They also cite the shift in consumer demand patterns (leisure travel increasingly favoring peak days, expanding RASM premium from 19% to over 25%) as direct evidence of customer preference that is reshaping capacity and margins. These elements are presented as the behavioral foundation for continued growth rather than merely company results or plans.
PCRX · Q4 2017 → YESThe question is: Does management ground their case for why the business is working and will keep growing in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in concrete, observed counterparty behavior—specifically J&J’s sales team activating accounts and training customers on EXPAREL technique, with the number of activated accounts continuing to grow, plus J&J committing to a six-fold increase in PEAK programs (already exceeding 2018 plans). They also cite commercial payers paying for EXPAREL under C9290 as a medical benefit and hospitals gaining access through surgeon relationships, treating these patterns as central proof that the offering is being chosen and valued, with the business still early and expanding ahead.
PPC · Q1 2024 → YESThe question is: Does management ground their case in OBSERVED CUSTOMER OR COUNTERPARTY BEHAVIOR from the recent period? YES Management grounds its case in observed counterparty behavior by citing concrete patterns such as key customers increasing marketplace presence, deli and QSRs showing steady performance, brands growing faster than category averages in Europe, key customer partnerships driving growth in Mexico, and key customers outpacing industry growth in domestic chicken volumes and value-added products — all presented as recent, specific actions by buyers and partners that demonstrate genuine preference and commitment, with the business still building further through continued diversification and new opportunities.